ZA200703751B - Ophthalmic oil-in-water type emulsion with stable positive zeta potential - Google Patents
Ophthalmic oil-in-water type emulsion with stable positive zeta potentialInfo
- Publication number
- ZA200703751B ZA200703751B ZA200703751A ZA200703751A ZA200703751B ZA 200703751 B ZA200703751 B ZA 200703751B ZA 200703751 A ZA200703751 A ZA 200703751A ZA 200703751 A ZA200703751 A ZA 200703751A ZA 200703751 B ZA200703751 B ZA 200703751B
- Authority
- ZA
- South Africa
- Prior art keywords
- zeta potential
- water type
- type emulsion
- positive zeta
- stable positive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04292645A EP1655021B1 (en) | 2004-11-09 | 2004-11-09 | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200703751B true ZA200703751B (en) | 2008-08-27 |
Family
ID=34931510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200703751A ZA200703751B (en) | 2004-11-09 | 2005-10-10 | Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
Country Status (14)
Country | Link |
---|---|
US (5) | US8298568B2 (zh) |
EP (1) | EP1655021B1 (zh) |
JP (3) | JP5587936B2 (zh) |
CN (3) | CN103356481B (zh) |
AT (5) | ATE412400T1 (zh) |
DE (5) | DE602004017477D1 (zh) |
DK (1) | DK1809237T3 (zh) |
ES (4) | ES2314354T3 (zh) |
HK (2) | HK1107938A1 (zh) |
IL (3) | IL181446A (zh) |
MX (2) | MX2007003045A (zh) |
NZ (1) | NZ554929A (zh) |
PT (2) | PT1809238E (zh) |
ZA (1) | ZA200703751B (zh) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8232320B2 (en) | 1999-04-28 | 2012-07-31 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
US7655252B2 (en) | 1999-04-28 | 2010-02-02 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
US20050208083A1 (en) | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
ATE412400T1 (de) * | 2004-11-09 | 2008-11-15 | Novagali Pharma Sa | Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential |
WO2006110699A1 (en) * | 2005-04-11 | 2006-10-19 | Nanobio Corporation | Quaternary ammonium halides for treatment of infectious conditions |
US7297679B2 (en) * | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
US20070036831A1 (en) * | 2005-08-09 | 2007-02-15 | Nanobio Corporation | Nanoemulsion compositions having anti-inflammatory activity |
US7797337B2 (en) * | 2005-09-29 | 2010-09-14 | Scenera Technologies, Llc | Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource |
US11311477B2 (en) | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
AU2007224006A1 (en) * | 2006-03-07 | 2007-09-13 | Novavax, Inc. | Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same |
CA2681668C (en) | 2006-03-23 | 2014-04-01 | Michael S. Singer | Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat |
US20080026013A1 (en) * | 2006-07-28 | 2008-01-31 | Laura Rabinovich-Guilatt | Compositions containing quaternary ammonium compounds |
US9132071B2 (en) * | 2006-07-28 | 2015-09-15 | Santen Sas | Compositions containing quaternary ammonium compounds |
AU2014201978B2 (en) * | 2006-07-28 | 2016-03-10 | Santen Sas | Compositions containing quaternary ammonium compounds |
WO2008035246A2 (en) | 2006-07-28 | 2008-03-27 | Novagali Pharma Sa | Compositions containing quaternary ammonium compounds |
PT1891939E (pt) * | 2006-07-28 | 2013-10-07 | Novagali Pharma Sa | Composições contendo compostos de amónio quaternário |
EP1901101A1 (en) | 2006-09-14 | 2008-03-19 | Carl Zeiss SMT AG | Optical element unit and method of supporting an optical element |
EP1938801A1 (en) * | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
EP1985298A1 (en) | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Ophtalmic oil-in-water emulsions containing prostaglandins |
EP2152304B1 (en) | 2007-05-02 | 2018-08-22 | The Regents of the University of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US20090018057A1 (en) * | 2007-07-09 | 2009-01-15 | Gregory Lambert | OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES |
US8512687B2 (en) * | 2007-07-09 | 2013-08-20 | Novagali Pharma Sa | Oil in water emulsion comprising NSAIDs and quaternary ammonium halides |
US9125807B2 (en) * | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
US9629852B2 (en) * | 2007-10-16 | 2017-04-25 | Sun Pharma Advanced Research Company Ltd. | Ophthalmic composition comprising a prostaglandin |
US7834172B2 (en) * | 2007-11-14 | 2010-11-16 | Novagali Pharma Sa | Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC |
WO2009063081A2 (en) * | 2007-11-14 | 2009-05-22 | Novagali Pharma Sa | Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc. |
EP2077105A1 (en) * | 2008-01-02 | 2009-07-08 | Novagali Pharma SA | Ophthalmic Micellar Compositions with Enhanced Stability |
EP2077104A1 (en) * | 2008-01-02 | 2009-07-08 | Novagali Pharma SA | Micellar compositions with ophtalmic applications |
EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
CA2735825C (en) * | 2008-09-04 | 2016-06-21 | Santen Pharmaceutical Co., Ltd. | Hair growth promoting agent containing 15,15-difluoroprostaglandin f2.alpha. derivative as active ingredient |
WO2010026239A1 (en) * | 2008-09-05 | 2010-03-11 | Ceva Sante Animale Sa | Composition comprising chitosan for ocular administration of vaccine(s) to avians |
CA2743904A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
JP5890182B2 (ja) | 2009-02-12 | 2016-03-22 | インセプト エルエルシー | ヒドロゲルプラグによる薬物送達 |
EP2228057A1 (en) * | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Cationic oil-in-water emulsions containing prostaglandins and uses thereof |
EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US20130011354A1 (en) * | 2009-11-09 | 2013-01-10 | Allergan, Inc. | Compositions For Enhancing Hair Growth |
EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
US10154923B2 (en) | 2010-07-15 | 2018-12-18 | Eyenovia, Inc. | Drop generating device |
WO2012009696A2 (en) * | 2010-07-15 | 2012-01-19 | Corinthian Ophthalmic, Inc. | Ophthalmic drug delivery |
US10272040B2 (en) | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
EP3378480A1 (en) | 2011-01-19 | 2018-09-26 | Topokine Therapeutics, Inc. | Methods and compositions for treating obesity |
ES2672238T3 (es) | 2011-01-26 | 2018-06-13 | Allergan, Inc. | Composición androgénica para el tratamiento de una afección oftálmica |
US10307292B2 (en) | 2011-07-18 | 2019-06-04 | Mor Research Applications Ltd | Device for adjusting the intraocular pressure |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
CN104080442B (zh) | 2011-11-15 | 2018-01-05 | 阿勒根公司 | 环孢菌素a形式2的悬浮液 |
CN104039308B (zh) | 2011-11-15 | 2018-06-05 | 阿勒根公司 | 环孢菌素a形式2的可热压性悬浮液 |
CA2858161C (en) | 2011-12-05 | 2020-03-10 | Incept, Llc | Medical organogel processes and compositions |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
WO2013125026A1 (ja) * | 2012-02-24 | 2013-08-29 | ファインバイオメディカル有限会社 | 潤滑性調整液 |
SI2887923T1 (sl) * | 2012-08-24 | 2023-09-29 | Sun Pharmaceutical Industries Limited | Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj |
EP2892564A4 (en) * | 2012-09-06 | 2016-04-27 | Univ Nanyang Tech | HYALURONIC ACID MEDICINE DELIVERY SYSTEMS |
CA2869676C (en) | 2012-11-21 | 2015-06-23 | Topokine Therapeutics, Inc. | Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat |
AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
CA3144684A1 (en) | 2013-03-05 | 2014-09-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery |
CN105073112B (zh) * | 2013-03-13 | 2017-12-29 | 参天制药株式会社 | 睑板腺功能障碍的治疗剂 |
US20140275261A1 (en) * | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
RU2513597C1 (ru) * | 2013-04-17 | 2014-04-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) | Способ лечения воспалительных состояний переднего отрезка глаза |
NO2753788T3 (zh) | 2013-05-10 | 2018-06-16 | ||
US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
EP3013790A1 (en) | 2013-06-27 | 2016-05-04 | Mylan Laboratories Ltd. | Process for the preparation of nepafenac |
US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
JP2017505349A (ja) | 2014-02-11 | 2017-02-16 | ドクター レディズ ラボラトリーズ リミテッド | セレコキシブの非経口組成物 |
CN106456541A (zh) | 2014-02-14 | 2017-02-22 | 黄敬珺 | 纳米乳传递系统组合物 |
JP2017517549A (ja) * | 2014-06-13 | 2017-06-29 | サノフイ | 活性薬剤成分のナノカプセル製剤 |
US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
PL3233174T3 (pl) * | 2014-12-19 | 2021-08-30 | Kemin Industries, Inc. | Wewnątrzgałkowe dostarczanie bioaktywnych cząsteczek za pomocą jontoforezy |
US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
EP3253372B8 (en) * | 2015-02-06 | 2022-06-22 | Woodstock Sterile Solutions, Inc. | Preparation of an oil-in-water emulsion for polymer stabilized pharmaceutical formulations |
CN106176600A (zh) * | 2015-05-07 | 2016-12-07 | 上海现代药物制剂工程研究中心有限公司 | 一种前列地尔冻干微乳剂、原料组合物及其制备方法 |
WO2016182926A1 (en) * | 2015-05-08 | 2016-11-17 | Affinsci Inc. | Preparation of nanoemulsions |
NZ755442A (en) | 2016-02-29 | 2023-04-28 | Sun Pharmaceutical Ind Ltd | Topical cyclosporine-containing formulations and uses thereof |
JP6906899B2 (ja) * | 2016-03-30 | 2021-07-21 | 小林製薬株式会社 | 乳化組成物 |
US11285285B2 (en) | 2016-05-03 | 2022-03-29 | Pneuma Respiratory, Inc. | Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment |
US11395853B2 (en) | 2016-06-23 | 2022-07-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions |
JOP20170147B1 (ar) * | 2016-07-07 | 2021-08-17 | Salvat Lab Sa | تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة |
CN106782348A (zh) * | 2017-01-04 | 2017-05-31 | 深圳市华星光电技术有限公司 | 一种led背光驱动电路及液晶显示器 |
WO2018129364A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
CN110799231B (zh) | 2017-05-19 | 2022-08-02 | 精呼吸股份有限公司 | 干粉输送装置及其使用方法 |
CA3065474A1 (en) * | 2017-05-30 | 2018-12-06 | Eximore Ltd. | Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide |
KR102643190B1 (ko) | 2017-06-10 | 2024-03-04 | 아이노비아 인코포레이티드 | 유체를 취급하기 위한, 그리고 눈에 유체를 전달하기 위한 디바이스들 |
WO2019071008A1 (en) | 2017-10-04 | 2019-04-11 | Pneuma Respiratory, Inc. | ELECTRONIC DEVICE FOR DELIVERY OF LINEAR SHAPE ADMINISTRATION OPERATED BY BREATHING AND METHODS OF USE |
WO2019079461A1 (en) | 2017-10-17 | 2019-04-25 | Pneuma Respiratory, Inc. | NASAL MEDICATION DELIVERY APPARATUS AND METHODS OF USE |
US11253480B2 (en) | 2017-10-30 | 2022-02-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor |
CA3082192A1 (en) | 2017-11-08 | 2019-05-16 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use |
KR20200130704A (ko) * | 2018-02-26 | 2020-11-19 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 약물 전달 시스템 |
WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
CN109010268B (zh) * | 2018-09-28 | 2020-07-10 | 湖北远大天天明制药有限公司 | 一种提高氯霉素稳定性的眼用组合物及其制备方法 |
JP7326445B2 (ja) | 2018-12-11 | 2023-08-15 | ディスラプション・ラブズ・インコーポレイテッド | 治療剤の送達のための組成物並びにその使用及び製造方法 |
CN110237233B (zh) * | 2019-07-30 | 2021-01-15 | 沈阳兴齐眼药股份有限公司 | 一种含有环孢素的眼用药物组合物、其制备方法及用途 |
MX2022006803A (es) * | 2019-12-04 | 2022-09-19 | Restore Vision Llc | Formulaciones oftalmicas para el tratamiento de la presbicia. |
AU2021286489A1 (en) * | 2020-06-10 | 2023-02-02 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
US11793945B2 (en) | 2021-06-22 | 2023-10-24 | Pneuma Respiratory, Inc. | Droplet delivery device with push ejection |
CN113577024B (zh) * | 2021-08-20 | 2023-05-05 | 山西利普达医药科技有限公司 | 一种眼用组合物及其制备方法和应用 |
CN116407499A (zh) * | 2021-12-29 | 2023-07-11 | 辅必成(上海)医药科技有限公司 | 一种他克莫司眼用乳剂及其制备方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
JPH0818989B2 (ja) * | 1984-01-12 | 1996-02-28 | 株式会社ミドリ十字 | 脂肪乳剤中のプロスタグランジンの安定化方法 |
US4839342A (en) * | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
JP2602964B2 (ja) | 1989-10-16 | 1997-04-23 | 裕 水島 | プロスタグランジン類縁体およびその脂肪乳剤 |
IL101241A (en) * | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
CA2142103C (en) * | 1992-08-28 | 2003-07-08 | Haim Aviv | Submicron emulsions as ocular drug delivery vehicles |
IL103907A0 (en) * | 1992-11-27 | 1993-04-04 | Pharmos Corp | Ophthalmic compositions |
US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
JP3551977B2 (ja) * | 1993-04-08 | 2004-08-11 | ライオン株式会社 | 安定なビタミンa類及びビタミンe類可溶化点眼剤 |
EP0631770B1 (en) * | 1993-06-25 | 1998-07-22 | Alcon Cusi, S.A. | New use of polymeric membranes in the dispensing of pharmaceutical solutions that contain quaternary ammonium compounds as preservatives and corresponding dose dispensor |
US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
RU2119351C1 (ru) * | 1994-06-01 | 1998-09-27 | Юхан Корпорейшн | Иммуносупрессорная композиция, содержащая циклоспорин, и способ ее получения |
ES2094688B1 (es) * | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
US5631287A (en) * | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
US6011062A (en) * | 1994-12-22 | 2000-01-04 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
US5767153A (en) * | 1995-06-07 | 1998-06-16 | Insite Vision Incorporated | Sustained release emulsions |
DE69807281T2 (de) | 1997-05-14 | 2003-04-17 | Senju Pharma Co | Difluprednat enthaltende Zusammensetzungen |
JP3410364B2 (ja) * | 1997-05-14 | 2003-05-26 | 千寿製薬株式会社 | ジフルプレドナート含有組成物 |
US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
US6225348B1 (en) * | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
AU2183900A (en) * | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
US20020136771A1 (en) * | 1998-12-31 | 2002-09-26 | Amitee Cosmetics, Inc. | Stabilized ascorbic acid composition |
FR2823441B1 (fr) * | 2001-04-12 | 2004-09-10 | Thea Lab | Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation |
WO2002085248A2 (en) * | 2001-04-23 | 2002-10-31 | Board Of Regents The University Of Texas System | Prostanoids augment ocular drug penetration |
JP2006512401A (ja) * | 2001-06-05 | 2006-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ナノエマルジョンワクチン |
US6872705B2 (en) * | 2001-07-13 | 2005-03-29 | Allergan, Inc. | Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions |
JP2005513097A (ja) * | 2001-11-01 | 2005-05-12 | イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム | ドライアイ治療方法および組成物 |
US6656460B2 (en) * | 2001-11-01 | 2003-12-02 | Yissum Research Development | Method and composition for dry eye treatment |
KR100446960B1 (ko) | 2001-12-04 | 2004-09-01 | 김종국 | 프로스타글란딘 e1을 포함하는 온도감응성 에멀젼 외용제조성물 |
US20030165545A1 (en) * | 2002-01-30 | 2003-09-04 | Allergan, Inc. | Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same |
US20050124699A1 (en) * | 2002-07-02 | 2005-06-09 | Wakamoto Pharmaceutical Co., Ltd. | Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells |
KR20100132557A (ko) | 2002-08-23 | 2010-12-17 | 산텐 세이야꾸 가부시키가이샤 | 라타노프로스트를 유효 성분으로 하는 점안액의 안정화 방법 |
KR20050057251A (ko) | 2002-09-09 | 2005-06-16 | 산텐 세이야꾸 가부시키가이샤 | 라타노프로스트를 유효 성분으로 하는 투명한 점안액 |
US20040115234A1 (en) * | 2002-09-24 | 2004-06-17 | Gewirtz Joan T. | Cosmetic composition |
US7074827B2 (en) * | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
JP4361294B2 (ja) * | 2003-02-25 | 2009-11-11 | ロート製薬株式会社 | ケトチフェン含有組成物 |
JP4694773B2 (ja) * | 2003-06-06 | 2011-06-08 | ロート製薬株式会社 | 粘膜適用液状組成物 |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
JP5382972B2 (ja) * | 2003-12-26 | 2014-01-08 | ロート製薬株式会社 | 粘度低下が防止された組成物 |
US20050175651A1 (en) * | 2004-01-09 | 2005-08-11 | L'oreal | Aqueous dispersion of nanocapsules with an oily core |
ATE439123T1 (de) | 2004-07-02 | 2009-08-15 | Novagali Pharma Sa | Verwendung von emulsionen zur intra- und periocularen injection |
JP4999304B2 (ja) * | 2004-09-27 | 2012-08-15 | ロート製薬株式会社 | ヒアルロン酸又はその塩を含有する粘膜適用組成物 |
ATE412400T1 (de) * | 2004-11-09 | 2008-11-15 | Novagali Pharma Sa | Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential |
EP1809238B1 (en) * | 2004-11-09 | 2008-10-29 | Novagali Pharma SA | Ophthalmic emulsions containing an immunosuppressive agent |
US20090170944A1 (en) * | 2008-01-02 | 2009-07-02 | Novagali Pharma Sa | Ophthalmic micellar compositions with enhanced stability |
US20090169629A1 (en) * | 2008-01-02 | 2009-07-02 | Novagali Pharma Sa | Micellar compositions with ophthalmic applications |
KR20110010788A (ko) * | 2008-05-28 | 2011-02-07 | 알콘 리서치, 리미티드 | 자기보존 에멀젼 |
EP2228057A1 (en) * | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Cationic oil-in-water emulsions containing prostaglandins and uses thereof |
EP2228058A1 (en) * | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
EP2389939A1 (en) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
-
2004
- 2004-11-09 AT AT04292645T patent/ATE412400T1/de not_active IP Right Cessation
- 2004-11-09 ES ES04292645T patent/ES2314354T3/es active Active
- 2004-11-09 EP EP04292645A patent/EP1655021B1/en active Active
- 2004-11-09 DE DE602004017477T patent/DE602004017477D1/de active Active
- 2004-11-18 US US10/991,346 patent/US8298568B2/en active Active
-
2005
- 2005-10-10 US US11/665,066 patent/US8298569B2/en active Active
- 2005-10-10 US US11/667,355 patent/US8372434B2/en active Active
- 2005-10-10 CN CN201310241506.7A patent/CN103356481B/zh active Active
- 2005-10-10 DE DE602005011480T patent/DE602005011480D1/de active Active
- 2005-10-10 MX MX2007003045A patent/MX2007003045A/es active IP Right Grant
- 2005-10-10 ES ES05802097T patent/ES2317319T3/es active Active
- 2005-10-10 DE DE602005010733T patent/DE602005010733D1/de active Active
- 2005-10-10 DE DE602005026464T patent/DE602005026464D1/de active Active
- 2005-10-10 CN CNA2005800300698A patent/CN101014317A/zh active Pending
- 2005-10-10 ES ES05800012T patent/ES2319129T3/es active Active
- 2005-10-10 US US11/667,129 patent/US8273362B2/en active Active
- 2005-10-10 PT PT05802097T patent/PT1809238E/pt unknown
- 2005-10-10 AT AT05802097T patent/ATE412401T1/de not_active IP Right Cessation
- 2005-10-10 DE DE602005012136T patent/DE602005012136D1/de active Active
- 2005-10-10 AT AT05795930T patent/ATE418964T1/de not_active IP Right Cessation
- 2005-10-10 ZA ZA200703751A patent/ZA200703751B/xx unknown
- 2005-10-10 AT AT05800012T patent/ATE415942T1/de not_active IP Right Cessation
- 2005-10-10 PT PT05795930T patent/PT1809237E/pt unknown
- 2005-10-10 MX MX2007005545A patent/MX2007005545A/es active IP Right Grant
- 2005-10-10 AT AT08102553T patent/ATE498392T1/de not_active IP Right Cessation
- 2005-10-10 DK DK05795930T patent/DK1809237T3/da active
- 2005-10-10 CN CN2005800383296A patent/CN101056615B/zh active Active
- 2005-10-10 ES ES05795930T patent/ES2320574T3/es active Active
- 2005-10-10 NZ NZ554929A patent/NZ554929A/en unknown
-
2006
- 2006-10-10 US US12/089,609 patent/US20080268020A1/en not_active Abandoned
-
2007
- 2007-02-20 IL IL181446A patent/IL181446A/en active IP Right Grant
- 2007-05-01 IL IL182897A patent/IL182897A/en unknown
-
2008
- 2008-01-21 HK HK08100777.1A patent/HK1107938A1/xx unknown
- 2008-03-27 IL IL190497A patent/IL190497A/en active IP Right Grant
- 2008-06-17 HK HK08106646.7A patent/HK1112411A1/xx unknown
-
2012
- 2012-04-05 JP JP2012086806A patent/JP5587936B2/ja active Active
- 2012-05-15 JP JP2012111941A patent/JP5773941B2/ja active Active
-
2014
- 2014-02-19 JP JP2014029816A patent/JP5894202B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200703751B (en) | Ophthalmic oil-in-water type emulsion with stable positive zeta potential | |
TWI366471B (en) | Compositions and methods for localized therapy of the eye | |
WO2006050837A3 (en) | Ophthalmic emulsions containing an immunosuppressive agent | |
BRPI0411306A (pt) | composições farmacêuticas compreendendo compostos ativos de vitamina d | |
WO2002083097A3 (en) | Drug delivery system for hydrophobic drugs | |
WO2004093795A3 (en) | Compositions for delivery of drug combinations | |
WO2008070538A3 (en) | Micellar nanoparticles comprising botulinum toxin | |
WO2007027941A3 (en) | Compositions and methods for preparation of poorly water soluble drugs with increased stability | |
MXPA05002814A (es) | Formulacion para agentes lipofilicos. | |
ES2134850T3 (es) | Emulsiones farmaceuticas o cosmeticas aceite en agua de particulas cargadas positivamente. | |
IL174561A0 (en) | Drug coating providing high drug loading and methods for providing the same | |
WO2006113505A3 (en) | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same | |
IL188774A0 (en) | Compositions for delivery of drug combinations | |
MX2009001461A (es) | Suministro por etapas multiples de agentes activos. | |
WO2008067164A3 (en) | Solid pharmaceutical dosage formulations | |
WO2005027822A3 (en) | Stabilized formulations of phosphatidylserine | |
WO2006050246A3 (en) | Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles, their manufacturing and their use for diagnostics and therapy | |
BRPI0504082A (pt) | emulsões refrescantes medicinais | |
WO2004071386A3 (en) | Compositions comprising microcapsules containing magnetic nanoparticles and biologically active molecules, their preparation and use | |
WO2006003519A3 (en) | Use of emulsions for intra: and periocular injection | |
IL149899A0 (en) | MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION HCl AS ACTIVE SUBSTANCE |